Johnson & Johnson suspended sales forecasts for its COVID-19 vaccine on April 19, citing a global supply surplus and uncertainty when it comes to future demand for the shot. The company had previously predicted as much as $3.5 billion in 2022 sales from the single-dose vaccine, but demand for the shot has dwindled behind that of the Moderna and Pfizer vaccines. In its quarterly earnings results on April 19, the company said the move will not impact shareholder earnings. Johnson & Johnson reported a better-than-expected first-quarter profit and also announced a 6.6 percent increase in the quarterly dividend from $1.06 per share to $1.13 per share, which will bring the annual payout to $4.52 per share, up from $4.24. ...
Source: https://www.theepochtimes.com/jj-suspen ... 15370.html
J&J Suspends Sales Forecast for COVID Vaccine Citing Uncertainty in Demand, Global Supply Surplus
-
claireokc
- Posts: 10998
- Joined: Wed Dec 01, 2021 11:40 pm
- Location: Deep in the Heart of Soonerland
- Has thanked: 2 times
- Contact:
J&J Suspends Sales Forecast for COVID Vaccine Citing Uncertainty in Demand, Global Supply Surplus
"America needs a brushfire, a moral and spiritual brushfire. And brushfires burn from the bottom up." ~ Bob Woodson